Psychedelics
One Month of Psilocybin Microdosing Improves Mood and Mental Health, Study Suggests
The microdosers in the study generally reported less depression, stress, and anxiety after one month of use, compared to their non-microdosing peers.
Launching the Cannabis and Psychedelics Industries: An Interview with Dr. Nigam B. Arora
Analytical Cannabis caught up with Dr. Arora to discuss his podcast, his role as an advisor to cannabis and psychedelic businesses, and what the future holds for both sectors.
Canadian Company Requests Approval To Manufacture MDMA, Other Synthetic Psychedelics
The move would enable the Company to synthesize, process and distribute pharmaceutical grade 3,4-Methylenedioxymethamphetamine (“MDMA”), among other substances, at its Princeton, British Columbia facility.
Mystical Psilocybin Trips Linked to Lasting Positive Psychological Effects, Study Finds
New research published in the journal Frontiers in Pharmacology has found that the mystical experiences induced by psilocybin are closely linked to long-lasting positive psychological effects in healthy individuals.
Psychedelics Can Help Boost Scientific Creativity, Review Finds
Can psychedelic drugs help scientists to solve their technical problems? Yes, according to one recent review.
Novel Psychedelic Molecule Shows Promise in Pre-Clinical Cocaine Addiction Treatment Trial
While effective treatments for opioid addictions have been available, this could be the first dedicated treatment for cocaine addiction, which is a global crisis.
British Columbia to Decriminalize Opioids, Cocaine, and MDMA
From next year, Canadians living in the province of British Columbia will be able to possess opioids, cocaine, methamphetamine, and MDMA, the country’s government has announced.
Psychedelics Company to Provide Free LSD to Researchers
The psychedelics company Ceruvia Lifesciences is offering to supply LSD, at no cost, to qualified researchers.
$2.7 Million Federal Grant Will Fund Study to Find New Psychedelics
Researchers from the University of California, Davis, and the University of Colorado Anschutz Medical Campus are about to start a new project to discover new, non-hallucinogenic treatments for substance use disorders.
